Blood Advances

Blood Advances is an online-only, fully open access journal of the American Society of Hematology, published by Elsevier and launched in 2016 as a companion to Blood, covering basic, translational and clinical hematology, with a 2025 Journal Impact Factor of 7.7 and a rank of 13th among 103 hematology journals《血液进展》（Blood Advances）是（American Society of Hematology）的纯在线开放获取期刊，2016 年创刊，由（Elsevier）出版，作为《血液》（Blood）的姊妹刊，覆盖基础、转化与临床血液学，2025 年影响因子为 7.7，在 103 种血液学期刊中列第 13 位。

Scope

• Clinical trials and observational studies in benign and malignant hematology are the core category, with an explicit home for health services and outcomes research良性与恶性血液学的临床试验和观察性研究是核心板块，并专设卫生服务与结局研究方向。
• Hematopoiesis and stem cell biology are covered alongside myelopoiesis, erythropoiesis and the bone marrow microenvironment造血与干细胞生物学与髓系生成、红细胞生成及骨髓微环境研究一并纳入。
• Myeloid and lymphoid neoplasia are treated as separate categories, spanning leukemia, myelodysplasia, myeloma and the lymphomas髓系与淋系肿瘤分列不同栏目，涵盖白血病、骨髓增生异常、骨髓瘤与各类淋巴瘤。
• Platelets and thrombopoiesis, red cells and iron metabolism, and transfusion medicine each have dedicated editorial coverage血小板与血小板生成、红细胞与铁代谢、输血医学各有专门的编辑分工。
• Thrombosis and hemostasis, vascular biology, and transplantation and cellular therapy complete the clinical portfolio血栓与止血、血管生物学以及移植与细胞治疗构成其余临床板块。
• Gene therapy and immunobiology are treated as standalone scientific categories, reflecting the growth of engineered cell products基因治疗与免疫生物学单列为科学门类，反映工程化细胞产品的发展。
• The journal deliberately publishes material that Blood does not carry, including case reports, point-counterpoint exchanges and online comment on published work该刊有意收录《血液》不予刊载的内容，包括病例报告、正反方辩论以及对已发表论文的在线评论。

History

• Blood Advances was launched in 2016 by the American Society of Hematology, which had been publishing Blood since 1946 and wanted a fast, fully electronic outlet该刊由（American Society of Hematology）于 2016 年创办；该学会自 1946 年起出版《血液》，希望另设一份快速、纯电子的发表平台。^[1]
• Robert S. Negrin served as the founding editor-in-chief from 2016 to 2021 and shaped the journal's category structure（Robert S. Negrin）于 2016 至 2021 年担任创刊主编，奠定了该刊的栏目结构。
• Open access was not an option added later but the founding model, so every article has been free to read from the first issue开放获取并非后来追加的选项，而是创刊即确立的模式，因此自首期起全部论文均可免费阅读。
• Enhanced graphics, video and moderated online discussion were built in from the start as alternatives to the print-era article format增强图形、视频与由编辑主持的在线讨论自始即被纳入，作为印刷时代论文格式之外的替代形态。
• Its impact factor moved from 6.686 in 2021 to 7.637 in 2022, 7.1 in 2024 and 7.7 in 2025该刊影响因子由 2021 年的 6.686 升至 2022 年的 7.637，2024 年为 7.1，2025 年为 7.7。
• Publication is continuous, with accepted articles posted individually and later gathered into issues该刊连续出版，录用论文先单篇上线，随后结集为各期。

Editors

• The editor-in-chief is Catherine M. Bollard of Children's National Hospital in Washington, DC, a specialist in cellular immunotherapy and transplantation现任主编为华盛顿特区（Children's National Hospital）的（Catherine M. Bollard），专长为细胞免疫治疗与移植。
• Andrew S. Weyrich of the Oklahoma Medical Research Foundation serves as deputy editor, with a research focus on platelet and vascular biology（Oklahoma Medical Research Foundation）的（Andrew S. Weyrich）任副主编，研究方向为血小板与血管生物学。
• Thirteen associate editors cover leukemia, lymphoma, myeloma, transplantation, transfusion and classical hematology across the United States, Europe, Canada and Australia13 位副编辑分工覆盖白血病、淋巴瘤、骨髓瘤、移植、输血与经典血液学，分布于美国、欧洲、加拿大与澳大利亚。
• A digital commissioning editor and a large editorial board of practising hematologists handle the journal's multimedia and review pipeline该刊设数字约稿编辑，并由大批执业血液学家组成编委会，负责多媒体内容与审稿流程。
• Authors unsure whether a paper fits the scope are invited to contact the editor-in-chief before submission, and scope enquiries go to the editorial department with an abstract作者若不确定稿件是否属于本刊范围，可在投稿前联系主编；范围咨询需附摘要发送至编辑部。